21,774 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,774 shares of the biopharmaceutical company's stock, valued at approximately $916,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 493 shares during the period. Human Investing LLC acquired a new position in Ultragenyx Pharmaceutical during the fourth quarter worth approximately $42,000. Van ECK Associates Corp raised its stake in Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 273 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at $83,000. Finally, Nomura Asset Management Co. Ltd. purchased a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at $93,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Thomas Richard Kassberg sold 6,028 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $253,778.80. Following the completion of the transaction, the executive vice president now directly owns 265,238 shares in the company, valued at approximately $11,166,519.80. This trade represents a 2.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Emil D. Kakkis sold 25,000 shares of the business's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $42.48, for a total value of $1,062,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,158,985 shares of the company's stock, valued at approximately $91,713,682.80. This represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 124,643 shares of company stock worth $5,256,268. Insiders own 5.80% of the company's stock.

Remove Ads

Ultragenyx Pharmaceutical Stock Up 9.2 %

Shares of Ultragenyx Pharmaceutical stock traded up $2.85 during trading hours on Wednesday, hitting $33.91. 2,063,234 shares of the company's stock traded hands, compared to its average volume of 804,512. Ultragenyx Pharmaceutical Inc. has a twelve month low of $29.60 and a twelve month high of $60.37. The company has a market cap of $3.18 billion, a PE ratio of -5.35 and a beta of 0.61. The stock has a 50 day simple moving average of $40.16 and a 200-day simple moving average of $45.45.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. As a group, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Piper Sandler reduced their price objective on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. Cantor Fitzgerald reiterated an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. JPMorgan Chase & Co. raised their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Finally, Wells Fargo & Company boosted their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research note on Friday, December 20th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of "Moderate Buy" and an average target price of $92.79.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.